{"schema_version":"secwatch.filing_event.v1","accession":"0001034842-26-000041","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2026-05-20T20:10:19+00:00","discovered_at":"2026-05-20T20:11:00.269114+00:00","generated_at":"2026-05-20T21:37:24.860341+00:00","sec_items":["5.02","5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Rigel shareholders approve equity plan amendments adding 860K shares; re-elect directors","bullets":["Stockholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares.","Stockholders approved amendment to 2000 ESPP, adding 360,000 shares.","Directors Alison Hannah, Walter Moos, Raul Rodriguez re-elected with >86% votes cast in favor.","Advisory say-on-pay approved with 9,013,480 votes for (87.5% of votes cast).","Ratification of Ernst & Young as FY2026 auditor passed with 12,590,773 votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001034842-26-000041","json":"https://secwatch.observer/filing/0001034842-26-000041.json","markdown":"https://secwatch.observer/filing/0001034842-26-000041.md","text":"https://secwatch.observer/filing/0001034842-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/rigl-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T21:37:24.860341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0229c4528a4be86d7ea9cb5a0cfa45836e914f20","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Ratification of Selection of Ernst & Young at the 2026-12-31 meeting.","evidence_excerpt":"Ratification of Selection of Ernst & Young The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 12,590,773 1,506,852 29,809 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-12-31"}],"fact_type":"shareholder_vote"},{"claim_id":"4db56975803c58da9fdd24bf425b3703a12d861d","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Say-on-Pay.","evidence_excerpt":"Say-on-Pay The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. For Against Abstain Broker Non-Votes 9,013,480 1,291,609 416,316 3,406,029","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"57dae4d67ec19e5ed4fc3dbe492dab0cf21f4c3c","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Election of Directors.","evidence_excerpt":"Election of Directors Each of the nominees for director, to serve until the Company’s 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows: Name of Director For Withheld Abstain Broker Non-Votes Alison Hannah, M.D. 9,202,113 1,469,709 49,583 3,406,029 Walter Moos, Ph.D. 10,436,673 242,736 41,996 3,406,029 Raul Rodriguez 10,486,503 192,614 42,288 3,406,029","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"938777827159e3d3fbde1cd5520aa3fae56b83e7","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Approval of the Amended 2018 Equity Incentive Plan.","evidence_excerpt":"Approval of the Amended 2018 Equity Incentive Plan The Company’s stockholders approved the Amended 2018 Equity Incentive Plan. For Against Abstain Broker Non-Votes 6,497,964 3,813,701 409,740 3,406,029","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"bba88d83b9f29c50c597fb64d2c862cd4303f10c","claim":"RIGEL PHARMACEUTICALS INC shareholders approved Approval of the 2000 Employee Stock Purchase Plan.","evidence_excerpt":"Approval of the 2000 Employee Stock Purchase Plan The Company’s stockholders approved the Amended 2000 Employee Stock Purchase Plan. For Against Abstain Broker Non-Votes 9,840,922 475,464 405,019 3,406,029","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/0001034842-26-000041-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}